Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600857 | 0.79 | UGT2B17 (0.36) | ALDH1A1MAPTGAAHSD17B10MAOB | |
| SCHEMBL29460452 | 0.79 | AHR (0.45) | MAPTGAAMAOBSMN1; SMN2 | |
| SCHEMBL23647892 | 0.76 | EGFR (0.35) | ALDH1A1MAPTMAOBSMN1; SMN2 | |
| SCHEMBL23012562 | 0.76 | MAPT (0.35) | ALDH1A1MAPTGAAHSD17B10MAOB | |
| SCHEMBL5535609 | 0.76 | MAOB (0.33) | ALDH1A1MAPTGAAHSD17B10MAOB | |
| SCHEMBL23648096 | 0.76 | EGFR (0.33) | MAOBSMN1; SMN2 | |
| SCHEMBL23729378 | 0.76 | ALDH1A1 (0.34) | ALDH1A1MAPTGAAHSD17B10MAOB | |
| SCHEMBL5535613 | 0.76 | SELL (0.39) | ALDH1A1MAPTGAAHSD17B10MAOB | |
| SCHEMBL21471819 | 0.73 | HTR2A (0.33) | — | |
| SCHEMBL31166552 | 0.72 | MAOB (0.35) | ALDH1A1MAPTMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| EP-4090660-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2022-11-23 | — | — | EP | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | ALDH1A1 1617/4885MAPT 4774/4885GAA 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.